Pfizer Files With FDA for Emergency Use of CCP Virus Vaccine

Pfizer Files With FDA for Emergency Use of CCP Virus Vaccine
Vials of COVID-19 vaccine and a medical syringe are seen in front of a displayed Pfizer logo on Oct. 31, 2020. Dado Ruvic/Reuters
Tom Ozimek
By Tom Ozimek, Reporter
Updated:

Pfizer and partner BioNTech on Friday submitted an application to the Food and Drug Administration (FDA) for emergency use authorization of their experimental CCP virus vaccine, making them the first to seek such approval.

“It is with great pride and joy and even a little relief that I can say that our request for emergency use authorization for our COVID-19 vaccine is now in the FDA’s hands,” Pfizer CEO Albert Bourla said in a video shared on Friday. “This is a historic day, a historic day for science and for all of us. It took just 248 days to get from the day we announced our plans to collaborate with BioNTech to our FDA submission day,” he added.

Tom Ozimek
Tom Ozimek
Reporter
Tom Ozimek is a senior reporter for The Epoch Times. He has a broad background in journalism, deposit insurance, marketing and communications, and adult education.
twitter
Related Topics